NO933037D0 - Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier - Google Patents

Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier

Info

Publication number
NO933037D0
NO933037D0 NO933037A NO933037A NO933037D0 NO 933037 D0 NO933037 D0 NO 933037D0 NO 933037 A NO933037 A NO 933037A NO 933037 A NO933037 A NO 933037A NO 933037 D0 NO933037 D0 NO 933037D0
Authority
NO
Norway
Prior art keywords
coli
colonization factor
equivalented
formaline
cfa
Prior art date
Application number
NO933037A
Other languages
English (en)
Other versions
NO307867B1 (no
NO933037L (no
Inventor
Jan Holmgren
Ann-Mari Svennerholm
Original Assignee
Jan Holmgren
Svennerholm Ann Mari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jan Holmgren, Svennerholm Ann Mari filed Critical Jan Holmgren
Publication of NO933037D0 publication Critical patent/NO933037D0/no
Publication of NO933037L publication Critical patent/NO933037L/no
Publication of NO307867B1 publication Critical patent/NO307867B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO933037A 1991-02-26 1993-08-25 FremgangsmÕte for fremstilling av et vaksinepreparat mot tarminfeksjon hos mennesker forÕrsaket av enterotoksigene E. coli- bakterier NO307867B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100556A SE9100556D0 (sv) 1991-02-26 1991-02-26 Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
PCT/SE1992/000110 WO1992014487A1 (en) 1991-02-26 1992-02-25 Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans

Publications (3)

Publication Number Publication Date
NO933037D0 true NO933037D0 (no) 1993-08-25
NO933037L NO933037L (no) 1993-08-25
NO307867B1 NO307867B1 (no) 2000-06-13

Family

ID=20381987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933037A NO307867B1 (no) 1991-02-26 1993-08-25 FremgangsmÕte for fremstilling av et vaksinepreparat mot tarminfeksjon hos mennesker forÕrsaket av enterotoksigene E. coli- bakterier

Country Status (22)

Country Link
US (1) US6558678B1 (no)
EP (1) EP0573527B1 (no)
JP (1) JP3169608B2 (no)
KR (1) KR100221452B1 (no)
AT (1) ATE170755T1 (no)
AU (1) AU663864B2 (no)
BG (1) BG61683B1 (no)
BR (1) BR9205677A (no)
CA (1) CA2104877C (no)
CZ (1) CZ281556B6 (no)
DE (1) DE69226944T2 (no)
DK (1) DK0573527T3 (no)
ES (1) ES2123550T3 (no)
FI (1) FI108775B (no)
HU (1) HU213924B (no)
NO (1) NO307867B1 (no)
OA (1) OA09865A (no)
RO (1) RO109819B1 (no)
RU (1) RU2127121C1 (no)
SE (1) SE9100556D0 (no)
SK (1) SK280919B6 (no)
WO (1) WO1992014487A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
SE9401921D0 (sv) * 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria
US7404961B2 (en) 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
US7094883B1 (en) 1996-08-02 2006-08-22 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
US5994078A (en) * 1997-07-31 1999-11-30 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
NZ547156A (en) * 2003-10-31 2009-08-28 Univ British Columbia Attenuation of A/E pathogen virulence by modulating expression of NleA
WO2007089205A1 (en) * 2006-02-01 2007-08-09 Sbl Vaccin Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
EP2711013A4 (en) * 2011-05-18 2015-03-04 Ajinomoto Kk IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
AU2011376755B2 (en) * 2011-09-12 2016-09-29 Scandinavian Biopharma Holding Ab Vaccine for protection against ETEC induced diarrhea comprising dmLT.
EP2750701B1 (en) 2011-09-12 2015-10-21 Scandinavian Biopharma Holding AB Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD62894A (no) *
DE1208038B (de) * 1963-08-01 1965-12-30 Wellcome Found Verfahren zur Herstellung von Impfstoffen gegen Coli-Infektionen
GB1472624A (en) 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4338298A (en) * 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
DK41885A (da) * 1985-01-31 1986-11-13 Slagteriernes Forskningsinst 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
IL79432A (en) * 1985-07-31 1992-05-25 Univ Leland Stanford Junior Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms
FI76484C (fi) 1986-02-03 1988-11-10 Osmo Norvasto Kundstol.
JPS6399020A (ja) 1986-06-05 1988-04-30 ベイラ−　カレツジ　オブ　メデイシン ワクチンとその製法
SU1723116A1 (ru) * 1988-04-15 1992-03-30 Оренбургский Государственный Медицинский Институт Штамм бактерий BacILLUS SUвтILIS, используемый дл получени препарата дл профилактики и лечени воспалительных процессов и аллергических заболеваний
KR900701152A (ko) * 1988-09-06 1990-12-01 원본미기재 유전자 변환식물, 이로부터 얻어진 조성물 및 그 제조방법
SE9401921D0 (sv) * 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria

Also Published As

Publication number Publication date
OA09865A (en) 1994-08-15
RU2127121C1 (ru) 1999-03-10
JPH06505730A (ja) 1994-06-30
FI108775B (fi) 2002-03-28
HU9302410D0 (en) 1993-11-29
HU213924B (en) 1997-11-28
SK280919B6 (sk) 2000-09-12
CA2104877A1 (en) 1992-08-27
CA2104877C (en) 2005-10-04
KR930703015A (ko) 1993-11-29
SK91093A3 (en) 1994-05-11
CZ174293A3 (en) 1994-04-13
ATE170755T1 (de) 1998-09-15
BR9205677A (pt) 1994-05-17
BG61683B1 (bg) 1998-03-31
NO307867B1 (no) 2000-06-13
NO933037L (no) 1993-08-25
WO1992014487A1 (en) 1992-09-03
FI933728A0 (fi) 1993-08-25
DE69226944D1 (de) 1998-10-15
EP0573527A1 (en) 1993-12-15
DK0573527T3 (da) 1999-06-07
AU1330892A (en) 1992-09-15
EP0573527B1 (en) 1998-09-09
KR100221452B1 (ko) 1999-09-15
DE69226944T2 (de) 1999-02-11
JP3169608B2 (ja) 2001-05-28
AU663864B2 (en) 1995-10-26
HUT67198A (en) 1995-02-28
FI933728A (fi) 1993-10-25
RO109819B1 (ro) 1995-06-30
US6558678B1 (en) 2003-05-06
SE9100556D0 (sv) 1991-02-26
BG98070A (bg) 1994-06-30
CZ281556B6 (cs) 1996-11-13
ES2123550T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
NO933037L (no) Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier
Talbot et al. Progress in the development of mastitis vaccines
Jonson et al. Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture
RU93053899A (ru) Способ получения композиции вакцины, способ профилактики кишечных инфекций
Mukhopadhaya et al. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response
Bratthall et al. Antigenic variation of Streptococcus mutans colonizing gnotobiotic rats
Matsumoto et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice
KANEMORI et al. The role of extracellular protease produced by Vibrio anguillarum
Lasaro et al. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli
Yamaguchi et al. Antibody formation against Salmonella flagella by an immune ribonucleic acid fraction
Ahmad et al. Evaluation of Staphylococcus aureus and Streptococcus agalactiae aluminium hydroxide adjuvanted mastitis vaccine in rabbits
Boesman-Finkelstein et al. Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine
US3885011A (en) Vaccine adjuvants
Shaughnessy et al. Production of Potent Inactivated Vaccines with Ultraviolet Irradiation: IV. Vaccination Against Bacillary Dysentery
RU2227160C1 (ru) Штамм бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
Guinée et al. Protective immunity against Vibrio cholerae infection in the rabbit
Yancey et al. Motility of the pathogen and intestinal immunity of the host in experimental cholera
RU2190424C1 (ru) Антигенный состав чумной химической вакцины
RU2285539C2 (ru) Молекулярная бивалентная вакцина для профилактики бруцеллеза и диарей, вызванных энтеропатогенными бактериями
Jansen et al. Priming and boosting of the rabbit intestinal immune system with live and killed, smooth and rough Vibrio cholerae cells
RU2058388C1 (ru) Штамм бактерий vibrio cholerae eltor jnaba, используемый для иммунопрофилактики холеры
Chander et al. A note: polyvalent radiovaccine against Salmonella
Holder et al. Oral Pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa
Fournier 3. Current Pandemics of Cholera and Strategy of Cholera Vaccines
Mackowiak Germ warfare